These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 30370446

  • 1. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
    Jian M, Du Q, Zhu D, Mao Z, Wang X, Feng Y, Xiao Z, Wang H, Zhu Y.
    J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
    [Abstract] [Full Text] [Related]

  • 2. MicroRNA expression profile of bromocriptine-resistant prolactinomas.
    Wu ZB, Li WQ, Lin SJ, Wang CD, Cai L, Lu JL, Chen YX, Su ZP, Shang HB, Yang WL, Zhao WG.
    Mol Cell Endocrinol; 2014 Sep; 395(1-2):10-8. PubMed ID: 25064468
    [Abstract] [Full Text] [Related]

  • 3. miR-93-5p targets Smad7 to regulate the transforming growth factor-β1/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma.
    Hu B, Mao Z, Du Q, Jiang X, Wang Z, Xiao Z, Zhu D, Wang X, Zhu Y, Wang H.
    Brain Res Bull; 2019 Jul; 149():21-31. PubMed ID: 30946881
    [Abstract] [Full Text] [Related]

  • 4. Curcumin Sensitizes Prolactinoma Cells to Bromocriptine by Activating the ERK/EGR1 and Inhibiting the AKT/GSK-3β Signaling Pathway In Vitro and In Vivo.
    Tang C, Zhu J, Yuan F, Yang J, Cai X, Ma C.
    Mol Neurobiol; 2021 Dec; 58(12):6170-6185. PubMed ID: 34463926
    [Abstract] [Full Text] [Related]

  • 5. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
    Wang S, Wang A, Zhang Y, Zhu K, Wang X, Chen Y, Wu J.
    BMC Endocr Disord; 2021 Nov 23; 21(1):235. PubMed ID: 34814904
    [Abstract] [Full Text] [Related]

  • 6. Long non-coding RNA TPT1-AS1 sensitizes breast cancer cell to paclitaxel and inhibits cell proliferation by miR-3156-5p/caspase 2 axis.
    Huang Y, Zheng Y, Shao X, Shi L, Li G, Huang P.
    Hum Cell; 2021 Jul 23; 34(4):1244-1254. PubMed ID: 33999360
    [Abstract] [Full Text] [Related]

  • 7. CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma.
    Wu N, Zhu D, Li J, Li X, Zhu Z, Rao Q, Hu B, Wang H, Zhu Y.
    J Endocrinol Invest; 2023 Aug 23; 46(8):1573-1587. PubMed ID: 36853491
    [Abstract] [Full Text] [Related]

  • 8. Bromocriptine Induces Autophagy-Dependent Cell Death in Pituitary Adenomas.
    Geng X, Ma L, Li Z, Li Z, Li J, Li M, Wang Q, Chen Z, Sun Q.
    World Neurosurg; 2017 Apr 23; 100():407-416. PubMed ID: 28137551
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells.
    Huang J, Zhang F, Jiang L, Hu G, Sun W, Zhang C, Ding X.
    Cancer Res Treat; 2017 Apr 23; 49(2):358-373. PubMed ID: 27488872
    [Abstract] [Full Text] [Related]

  • 10. MiR-137's Tumor Suppression on Prolactinomas by Targeting MITF and Modulating Wnt Signaling Pathway.
    Lei C, Jing G, Jichao W, Xiaohui L, Fang Q, Hua G, Yazhou M, Zhang Y.
    J Clin Endocrinol Metab; 2019 Dec 01; 104(12):6391-6402. PubMed ID: 31162548
    [Abstract] [Full Text] [Related]

  • 11. Long noncoding RNA TPT1-AS1 downregulates the microRNA-770-5p expression to inhibit glioma cell autophagy and promote proliferation through STMN1 upregulation.
    Jia L, Song Y, Mu L, Li Q, Tang J, Yang Z, Meng W.
    J Cell Physiol; 2020 Apr 01; 235(4):3679-3689. PubMed ID: 31637705
    [Abstract] [Full Text] [Related]

  • 12. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
    Tang C, Sun R, Wen G, Zhong C, Yang J, Zhu J, Cong Z, Luo X, Ma C.
    Cell Death Dis; 2019 Apr 18; 10(5):335. PubMed ID: 31000722
    [Abstract] [Full Text] [Related]

  • 13. Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl‑xL signaling pathways.
    Xiao Z, Liang J, Deng Q, Song C, Yang X, Liu Z, Shao Z, Zhang K, Wang X, Li Z.
    Int J Mol Med; 2021 Jan 18; 47(1):113-124. PubMed ID: 33155660
    [Abstract] [Full Text] [Related]

  • 14. microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment.
    Wang C, Su Z, Sanai N, Xue X, Lu L, Chen Y, Wu J, Zheng W, Zhuge Q, Wu ZB.
    Oncol Rep; 2012 May 18; 27(5):1312-20. PubMed ID: 22366961
    [Abstract] [Full Text] [Related]

  • 15. Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas.
    Bai J, Gui S, Zhang Y.
    J Clin Neurosci; 2013 May 18; 20(5):721-5. PubMed ID: 23523357
    [Abstract] [Full Text] [Related]

  • 16. circOMA1-Mediated miR-145-5p Suppresses Tumor Growth of Nonfunctioning Pituitary Adenomas by Targeting TPT1.
    Du Q, Hu B, Feng Y, Wang Z, Wang X, Zhu D, Zhu Y, Jiang X, Wang H.
    J Clin Endocrinol Metab; 2019 Jun 01; 104(6):2419-2434. PubMed ID: 30721952
    [Abstract] [Full Text] [Related]

  • 17. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
    Gao H, Wang F, Lan X, Li C, Feng J, Bai J, Cao L, Gui S, Hong L, Zhang Y.
    BMC Cancer; 2015 Apr 12; 15():272. PubMed ID: 25884948
    [Abstract] [Full Text] [Related]

  • 18. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
    Cai L, Leng ZG, Guo YH, Lin SJ, Wu ZR, Su ZP, Lu JL, Wei LF, Zhuge QC, Jin K, Wu ZB.
    Endocrine; 2016 Jun 12; 52(3):641-51. PubMed ID: 26662185
    [Abstract] [Full Text] [Related]

  • 19. Guizhi Fuling pills inhibit the proliferation, migration and invasion of human cutaneous malignant melanoma cells by regulating the molecular axis of LncRNA TPT1-AS1 / miR-671-5p.
    Zhang B.
    Cell Mol Biol (Noisy-le-grand); 2020 Jul 31; 66(5):148-154. PubMed ID: 33040829
    [Abstract] [Full Text] [Related]

  • 20. Long non-coding RNA TPT1-AS1 promotes cell growth and metastasis in cervical cancer via acting AS a sponge for miR-324-5p.
    Jiang H, Huang G, Zhao N, Zhang T, Jiang M, He Y, Zhou X, Jiang X.
    J Exp Clin Cancer Res; 2018 Jul 25; 37(1):169. PubMed ID: 30045766
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.